Chronic Hepatitis (CHB) Epidemiology

DelveInsight's " Chronic Hepatitis (CHB)- Epidemiology Forecast-2034" report delivers an in-depth understanding of CHB, historical and forecasted epidemiology as well as the CHB market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan and China.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan
• China

Study Period: 2021-2034

Chronic Hepatitis B (CHB) Understanding

The DelveInsight’s Chronic Hepatitis B epidemiology report gives a thorough understanding of CHB. Hepatitis B is a liver infection caused by the hepatitis B virus. Some people with hepatitis B are sick for only a few weeks (known as “acute” infection), but for others, the disease progresses to a serious, lifelong illness known as chronic hepatitis B. Acute hepatitis B is a short-term illness that occurs within the first 6 months after someone is exposed to the hepatitis B virus. For people who are not able to clear the virus from their bodies without treatment, acute hepatitis B leads to a life-long infection known as chronic hepatitis B. Chronic hepatitis B is a heterogeneous disease with markedly variable levels of viral replication and liver disease. It is characterized by liver injury mediated by a T-cell immune response targeting hepatocytes that express viral antigens. It can lead to the development of chronic hepatitis, cirrhosis, and liver cancer.

Chronic hepatitis B is usually asymptomatic. The most common symptom is fatigue, but sleep disturbances, difficulty concentrating, and upper right quadrant pain are often observed.

Chronic infection may go undetected for decades until a person becomes seriously ill from liver disease. If signs of liver damage are present, the doctor will perform several tests to diagnose chronic hepatitis B, including blood tests to detect signs of hepatitis B virus in the body and liver ultrasound and biopsy to determine the amount of liver damage. Doctors sometimes also test certain healthy people for hepatitis B infection because the virus can damage the liver before causing signs and symptoms.

Continued in the report…

Chronic Hepatitis B (CHB) Epidemiology

The epidemiology section provides insights into the historical and current CHB patient pool and forecasted trends for individual seven major countries and China. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• The disease epidemiology covered in the report provides a historical as well as forecasted CHB epidemiology scenario in the 7MM covering the United States, EU4 countries, and the United Kingdom, Japan, and China from 2021 to 2034.
• In 2021, the total diagnosed prevalent cases of CHB were approximately 19,662,165 in the 7MM and China which is expected to grow during the study period, i.e., 2021-2034.
• The disease epidemiology covered in the report provides historical as well as forecasted CHB epidemiology [segmented as Prevalent cases of CHB, Diagnosed prevalent cases of CHB, Gender-specific cases of CHB, Age-specific cases of CHB, Type-specific cases of CHB, and Total treated cases of CHB] in the 7MM covering the United States, EU4 countries and the United Kingdom, Japan, and China from 2021 to 2034.

Country Wise- Chronic Hepatitis B (CHB) Epidemiology

The epidemiology segment also provides the CHB epidemiology data and findings across the United States, EU4 and the United Kingdom, Japan, and China.

KOL- Views

To keep up with the current CHB patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the CHB domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report

• The report covers a descriptive overview of CHB, explaining its causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 countries, the United Kingdom, Japan, and China.
• The report assesses the disease risk and burden and highlights the unmet needs of CHB.
• The report helps to recognize the growth opportunities in the 7MM and China concerning the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM and China by Prevalent cases of CHB, Diagnosed prevalent cases of CHB, Gender-specific cases of CHB, Age-specific cases of CHB, Type-specific cases of CHB, and Total treated cases of CHB in the 7MM covering the United States, EU4 countries and the United Kingdom, Japan and China from 2021 to 2034.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence CHB R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CHB.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chronic Hepatitis B (CHB) Report Key Strengths

• 10 Years Forecast
• 7MM and China Coverage
• CHB Epidemiology Segmentation

Key Questions

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of CHB?
• What are the key factors driving the epidemiology trend for Seven Major Markets and China covering the United States, EU4 and the United Kingdom, Japan, and China?
• What is the historical CHB Patient pool in Seven Major Market and China covering the United States, EU4, the United Kingdom, Japan, and China?
• What would be the forecasted patient pool of CHB in Seven Major Markets and China covering the United States, EU4, the United Kingdom, Japan, and China?
• Where will be the growth opportunities in the 7MM and China concerning the patient population of CHB?
• Out of all 7MM countries and China, which country would have the highest prevalent population of CHB during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM and China during the forecast period (2025-2034)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the CHB Disease market
• To understand the future market competition in the CHB Disease market
• Organize sales and marketing efforts by identifying the best opportunities for CHB Disease in the US, the EU4, the UK, Japan, and China
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the CHB Disease market
• To understand the future market competition in the CHB Disease market